Skip to main content
. 2022 Jun 25;22:701. doi: 10.1186/s12885-022-09776-x

Table 3.

CNS relapse presentation, treatment, and course of disease

Pt Time from diagnosis to CNS relapse (months) Relapse presentation Relapse therapy Disease status and time to relapse Disease course after relapse
1 5

Facial nerve palsy, strabismus

Tumour in CT

NBL cells in CSF and in removed tumour

Surgery, RTX, chemotherapy, intrathecal chemotherapy CR; on treatment after induction and surgery Local progression 6 months from relapse, death 7 months from relapse
2 6

Intracranial bleeding

No tumour in CT

NBL cells in removed tumour

Surgery CR; on treatment – before HDC Died 2 weeks after event
3 5

Accidental diagnosis

CT: infiltration of meninges, bleeding into the tumour

Chemotherapy, intrathecal chemotherapy

PR; on treatment -

after induction

Died 3 weeks after event bleeding into tumour
4 12

Intracranial bleeding

No radiological symptoms

NBL in postmortem examination

No therapy

CR; on treatment -

therapy of MRD

Died 5 days after event
5 8

Headache, nausea, vomiting

Tumour in CT

NBL cells in removed tumour

Surgery, radiotherapy, chemotherapy, 13 cis RA CR; after end of treatment CR in CNS; disseminated bone relapse 39 months after relapse; no 3rd line treatment. Died of disease
6 15 Facial nerve palsy Chemotherapy PR; on treatment – therapy of MRD Local progression and death 3 months after relapse
7 26

Headache, nausea, vomiting

Tumour in CT

Chemotherapy, radiotherapy, no surgery (tumour regression on chemotherapy) CR; after end of treatment Alive in CR > 9 years after relapse
8 8

Intracranial bleeding

No radiological symptoms

NBL in postmortem examination

No therapy CR; on treatment – after radiotherapy Died 2 days after event
9 20

Headache, nausea, vomiting

2 tumours in CT

NBL cells in removed tumour

Surgery, chemotherapy, radiotherapy, ibritumomab CR; 3 months after end of treatment Alive in CR, 2,5 years after relapse
10 8

Intracranial bleeding

No radiological symptoms

NBL in postmortem examination

No therapy PR; on treatment – after HDC, before ASCR Died 7 days after event
11 16

Headache

3 metastases in CT

No therapy CR, during immunotherapy Died of disease 3 months after event
12 14

No symptoms; mild headache on a day of planned CT

Tumour on CT – routine screening

Surgery, chemotherapy, radiotherapy CR: during immunotherapy Alive, 2nd CNS relapse after 9 months
13 20

Headache, vomiting

Infiltration of meninges in MRI, NBL cells in cerebrospinal fluid

Chemotherapy, radiotherapy CR; 6 months after end of immunotherapy Died of disease progression

Dx diagnosis, NBL neuroblastoma, CNS central nervous system, CT computed tomography, RTX radiotherapy, CR complete remission, PR partial remission, MRD minimal residual disease, MRI magnetic resonance imaging